glucose, (beta-d)-isomer has been researched along with Cardio-Renal Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, C; Cai, S; Li, Z; Ou, Q; Peng, L; Peng, X; Shi, N; Tan, Y; Wang, J; Wu, F; Zhuang, B | 1 |
| Burtey, S; Dou, L | 1 |
| Chang, HW; Chen, KH; Chen, YT; Cheng, BC; Ko, SF; Li, YC; Sung, PH; Wallace, CG; Yang, CC; Yip, HK | 1 |
3 other study(ies) available for glucose, (beta-d)-isomer and Cardio-Renal Syndrome
| Article | Year |
|---|---|
Empagliflozin activates Wnt/β-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance against type-3 cardiorenal syndrome.
Topics: Acute Kidney Injury; Animals; Benzhydryl Compounds; beta Catenin; Cardio-Renal Syndrome; Glucosides; Membrane Proteins; Mice; Mice, Knockout; Mitochondria; Mitochondrial Proteins; Wnt Proteins | 2022 |
Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome.
Topics: Benzhydryl Compounds; Cardio-Renal Syndrome; Endothelial Cells; Endothelium; Glucosides; Humans; Myocytes, Cardiac; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat.
Topics: Animals; Benzhydryl Compounds; Cardio-Renal Syndrome; Drug Administration Schedule; Glucosides; Heart; Kidney; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors | 2019 |